Taysha Gene Therapies Inc (NASDAQ: TSHA) on Monday, soared 6.77% from the previous trading day, before settling in for the closing price of $1.92. Within the past 52 weeks, TSHA’s price has moved between $1.19 and $4.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 129.39% over the last five years. The company achieved an average annual earnings per share of 61.44%. With a float of $153.61 million, this company’s outstanding shares have now reached $204.94 million.
The firm has a total of 52 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.01%, operating margin of -880.73%, and the pretax margin is -229.67%.
Taysha Gene Therapies Inc (TSHA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Taysha Gene Therapies Inc is 25.05%, while institutional ownership is 69.39%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares.
Taysha Gene Therapies Inc (TSHA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 61.44% per share during the next fiscal year.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Taysha Gene Therapies Inc (TSHA) is currently performing well based on its current performance indicators. A quick ratio of 5.51 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 44.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.03, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Analysing the last 5-days average volume posted by the [Taysha Gene Therapies Inc, TSHA], we can find that recorded value of 2.04 million was lower than the volume posted last year of 2.14 million. As of the previous 9 days, the stock’s Stochastic %D was 79.39%. Additionally, its Average True Range was 0.19.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 40.57%, which indicates a significant decrease from 84.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.56% in the past 14 days, which was lower than the 102.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0900, while its 200-day Moving Average is $2.4000. Now, the first resistance to watch is $2.1200. This is followed by the second major resistance level at $2.1800. The third major resistance level sits at $2.3100. If the price goes on to break the first support level at $1.9300, it is likely to go to the next support level at $1.8000. Now, if the price goes above the second support level, the third support stands at $1.7400.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
Market capitalization of the company is 436.03 million based on 204,943K outstanding shares. Right now, sales total 15,450 K and income totals -111,570 K. The company made 1,790 K in profit during its latest quarter, and -25,520 K in sales during its previous quarter.
